Peter D. Meldrum
Directeur Général chez Myriad GmbH
Profil
Peter D.
Meldrum was the founder of Myriad Genetics, Inc. founded in 1991, where he held the titles of President, Chief Executive Officer & Director from 2010 to 2015.
He is currently a Director at Prolexys Pharmaceuticals, Inc. and Co-Managing Director at Myriad GmbH.
Mr. Meldrum's former positions include President & Chief Executive Officer at The Founders Fund, Inc., Director at SINTX Technologies, Inc., and Director at Endocyte, Inc. He received an MBA in 1974 and an undergraduate degree in 1970 from the University of Utah.
He also received a doctorate from the University of Utah and Westminster College (Utah).
Postes actifs de Peter D. Meldrum
| Sociétés | Poste | Début |
|---|---|---|
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Directeur/Membre du Conseil | - |
Myriad GmbH
 Myriad GmbH Medical/Nursing ServicesHealth Services Part of Myriad Genetics, Inc., Myriad GmbH is a German company that provides health care services. The company is based in Munich, Germany. The CEOs of the company are Nathan Alan Smith, Peter D. Meldrum, Raymond Francot. | Directeur Général | - |
Anciens postes connus de Peter D. Meldrum
| Sociétés | Poste | Fin |
|---|---|---|
| MYRIAD GENETICS, INC. | Fondateur | 30/06/2015 |
| ENDOCYTE, INC. | Directeur/Membre du Conseil | - |
The Founders Fund, Inc.
 The Founders Fund, Inc. Miscellaneous Commercial ServicesCommercial Services The Founders Fund, Inc. provides financial assistance to students. It offers scholarships and sponsoring solutions to students for them to defray the cost of attending colleges, universities, and professional programs. The company was founded in 1991 and is headquartered in Naples, FL. | President | - |
| SINTX TECHNOLOGIES, INC. | Directeur/Membre du Conseil | - |
Formation de Peter D. Meldrum
| University of Utah | Masters Business Admin |
| Westminster College (Utah) | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MYRIAD GENETICS, INC. | Health Technology |
| SINTX TECHNOLOGIES, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
The Founders Fund, Inc.
The Founders Fund, Inc. Miscellaneous Commercial ServicesCommercial Services The Founders Fund, Inc. provides financial assistance to students. It offers scholarships and sponsoring solutions to students for them to defray the cost of attending colleges, universities, and professional programs. The company was founded in 1991 and is headquartered in Naples, FL. | Commercial Services |
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Myriad GmbH
Myriad GmbH Medical/Nursing ServicesHealth Services Part of Myriad Genetics, Inc., Myriad GmbH is a German company that provides health care services. The company is based in Munich, Germany. The CEOs of the company are Nathan Alan Smith, Peter D. Meldrum, Raymond Francot. | Health Services |
